Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Plant-based price parity will lead to exponential growth, study finds
https://www.fooddive.com/news/plant-based-price-parity-will-lead-to-exponential-growth-study-finds/620690/
Dive Brief:
Once plant-based meat reaches price parity with the animal-derived variety, its market share will grow exponentially, according to a study from Kearney. According to an analysis from agricultural economist Jayson Lusk, every 1% drop in price for plant-based patties leads to a 3% increase in market share.
Price parity isn't all that far away, Kearney analysts said. Many plant-based meat makers are close to paying off their start-up R&D costs, and some of the larger companies are instituting across-the-board price reductions. At the same time, traditional animal meat is getting more expensive because of inflation — something Kearney said hasn't happened so much to plant-based analogs.
Plant-based meat was a hot category with consistently growing sales through the first half of 2021, but sales have cooled considerably in the past six months. Publicly traded Beyond Meat and Maple Leaf Foods, parent company of Greenleaf Foods, both recently reported flat or negative growth in the segment.
Dive Insight:
This report brings a piece of good news to the plant-based meat sector: Despite recent slowdowns, serious growth may be around the corner. And unlike before, when the segment was relatively small and massive growth rates were easier to achieve, this expansion could actually make a serious dent in the meat industry.
It's all a matter of price, Kearney's report says. The management consulting firm found that three-quarters of consumers were likely to purchase plant-based products in the next year, with four in 10 saying they were very likely to buy them. The remaining 25% had two big reasons they didn't want to buy the products: They don't taste good and they're too expensive. More than half — 53% — said price is a limiting factor.
Plant-based meat companies have been working hard toward getting to price parity. Last year, Impossible Foods slashed its recommended grocery store prices by a fifth. The company also had two 15% price cuts for foodservice distributors in 2020 and 2021. Company President Dennis Woodside said in a blog post at the time of the grocery store price cut that Impossible always had the goal of driving down production costs as the company scales — and then being able to price its products cheaper than the meat they mimic. As people buy more Impossible Burgers, Woodside wrote, it fuels a "virtuous cycle" so they cost less to everyone.
The other giant in plant-based meat, Beyond Meat, is also making efforts toward price parity. The company set a goal to get at least one of its products there by 2024, and CEO Ethan Brown said last month in Beyond Meat's most recent earnings call that it was well on its way. New processes and R&D had helped lower input prices in the last year, he said, and more is coming.
The implications of players like Impossible and Beyond Meat hitting price parity are huge: If plant-based and traditional meat cost the same, Kearney estimated, plant-based patties could have a 10% market share for beef, and 22% for all animal protein.
Other consultants and investors also see price parity on the horizon. A report last year from investment firm Blue Horizon Corporation and Boston Consulting Group sees plant-based products reaching parity in 2023 — something that will speed mass adoption of the segment. The report estimates that at least 11% of all protein consumed in 2035 will be alternatives. With the right regulatory and government support, the report predicts meat consumption in the U.S. and Europe could actually start declining after 2025.
Regardless of what is happening in the plant-based meat sector, animal meat prices have also been rising, which acts to speed the drive to price parity as well. Supply chain, weather, inflation and personnel shortages have all come together to inch up the price of meat. According to statistics kept by the USDA, the price of a pound of ground beef has gone up 76 cents — or about 21% — between February 2020 and February 2022. Although a recent study commissioned by Ingredient Communications found that consumers would be willing to accept price increases of 50.6% before they stopped buying meat, decreasing costs for plant-based meats may erode this limit.
RIBT I wish it was going up on all it's own merits. But like at Twitter, it's tied a lot to a basket of small "Food Shortage stocks, WEAT and RKDA and others.
Maybe to much ay once. And tied to the "food shortage" stories. if a big deal is announced, today will look like chicken feed.
https://stockcharts.com/h-sc/ui?s=RIBT&p=D&yr=1&mn=0&dy=0&id=p49985889017
EVRNF(China Realestate) Desperate Evergrande Bondholders Threaten Lawsuit After Lenders Seize $2 Billion
https://finance.yahoo.com/quote/EGRNF/?p=EGRNF
https://www.zerohedge.com/markets/desperate-evergrande-bondholders-threaten-lawsuit-after-lenders-seize-2-billion
Following yesterday's revelation that an unspecified lender had seized more than $2 billion in cash deposits belonging to one of China Evergrand Group's subsidiaries, investors who own the firm's badly battered foreign-currency denominated bonds are reportedly examining legal avenues to recouping their capital, according to the FT.
A group of distressed debt investors in the US and UK (including Saba Capital, Redwood Capital Management and Ashmore) met on Tuesday and asked their lawyers to start work on a legal analysis of the situation in order to decide on a strategy. Evergrande and its subsidiaries trade in Hong Kong.
One of the FT's sources said the funds had been conspiring to try and find a legal avenue to force Evergrande to make good on its bonds in default before the company disclosed the seizure of $2 billion by unspecified lenders: the bonds represent $20 billion of foreign-currency debt, and are presently trading at a fraction of their face value. Evergrande has said it's hoping to offer up a debt-restructuring plane by July.
News of the $2 billion seizure infuriated bond holders, who will ultimately be saddled with losses if Evergrande ultimately fails to repay. Bondholders believe that the debt covenants entitles them to priority repayment over whatever lender seized the money.
One person directly involved in the situation said investors feel they have "no choice" but to commence legal action and that plans were already prepared. "I think it has massively changed the game, "the person said about the $2bn claim. "The atmosphere in the room is one of boiling blood."
All told, the Chinese developer owes more than $300 billion, and the firms push toward restructuring represents the biggest debt-restructuring in Chinese history.
Bondholders are also reportedly embracing the argument that the money seized by the firm's lenders would have been put to better use to pay off the bond obligations.
But while bondholders could be let holding the bag for billions, the incident represents a windfall for law firm Kirkland & Ellis and investment bank Moelis & Company.
The process has already been fraught with difficulty: Evergrande’s default, which began with missed payments in September but wasn't officially confirmed by one of the major US ratings agencies until December, has been characterized by a lack of disclosure and international investors have often been left in the dark
Another reason for the company's troubles: the CCP has prioritized the completion of Evergrande's apartment complexes over improving the company's financial position.
Evergrande held a call with investors last night, but few details about its plans were reportedly disclosed. One person who participated described it as "if a politician were addressing 15,000 people."
Investors and economists are closely watching the situation since China's heavily indebted property sector has led to speculation by some that the firm's default and eventual collapse could trigger China's "Lehman moment".
Copy, on March 10th we did 16,667,300 shares
The all time was 162,285,400 on April 27th last year. That is like trading 3.6 times the total shares then of approximately 45,000,000, lol
We could excedd that with a big reverse merger with Impossbile or patnership with Natula. Neither day of the big ones above had any news.
https://finance.yahoo.com/quote/RIBT/history?p=RIBT
110,000 shares already traded at 3 minutes after the open. That must have been besdin.
Dew, I smiled at "Chief Visionary Officer" myself. I'm thinking more now that it is a sign Impossible Foods is preparing for an IPO. I would not look for an IPO soon since the CEO should know a bit about the company first before and IPO?
$6.00? Wimp
Weekender: Nearly 80% of food and beverage companies have passed on higher costs to customers, survey finds
https://mail.google.com/mail/u/0/#inbox/FMfcgzGmvTzffnSxBGSQWPSDKggQzTld
Weekender: Nearly 80% of food and beverage companies have passed on higher costs to customers, survey finds
https://mail.google.com/mail/u/0/#inbox/FMfcgzGmvTzffnSxBGSQWPSDKggQzTld
tai, you will find the vieo below of interest on the tie with Continental Grain and Impossible. I saw the video below in March 2018 right before the conferece call. The video is from June 2017 and Continental bought into RIBT 4 months later. In the March 2018 CC I got a call in to the CC and I was asking about disruptive food technology. I got to where I feel they thought I was going to say "Impossible Foods", I was not going to mention them by name,but me as the 4th and possbily last caller, they shut the call down. The transcript said "Abrupt end". early the next week management bought more shares, then Continental bought a bunch more. I thought at first that they did not want me to make the Continental/Impossible connection, but it could have been it might have raised the share price and they did not want that. But, geezs, that was 4 years ago and plant based protein has spread everywhre but not all the eway in Asia.
Link 2 below scroll down to partenrships and see Bunge on page one. Clock the little orange arrow twice and see RIBT as a partner. I think it possible that Bunge does something with RIBT too as Continental's CEO Paul Fribourg sits on Bunge's BOD, and in 2018 saved Bunge from a hostile takeover by ADM. But nothing yet. Scroll down to the next section and see "Ventures" and on page 1 is Impossible Foods.>>>
https://continentalgrain.com/business/
Video watch, the first 8 minutes for sure and listen for the BINGO starti 1:15 mark for a few secongs at the 1:14 mark. But that was all 5 years and I think Continental could have other plans than Impossible. Narula would be bigger in my mind and could include Impossible. BYT, Narula is private as well, could they do a reverse merger with RIBT? I believe more of a partnersip is likely, not merger.
https://www.youtube.com/watch?v=pNG1Q7d7uIw&t=113s&ab_channel=MilkenInstitute
tai, I hope they get a deal in India. RIBT had an organic rice ban deal with Urmatt from 2010 until last year, and it might still be alive as far as I know.>>>
https://www.seair.co.in/us-import/product-rice-bran/e-urmatt-ltd.aspx
Urmatt is controlled my Narula, a huge India conglomerate, approved by their government. Narula is private, so little news. They are into healthcare>>>
https://thesiliconreview.com/magazine/profile/sng-sun-narula-group-bringing-smartsolutions-to-indian-healthcare-sector
Many other things and Food>>>
https://www.dnb.com/business-directory/company-profiles.narula_foods_private_limited.b9bbe9fc836b30d3030d6c12ced85db7.html
Bradley brought Narula up at an earlier CC in 2021. He said as best as I can recall, "We are hoping to make several rice bran products with them". It was like not a done deal and it could be dead, or stalled off because of the Ukraine stuff.
tai, RIBT would be much better off with Narula than Impossible. Impossible just got a new CEO and maybe struggling like BYND. Either way, RIBT could sell to Impossible in China through Narula possibly, plus make other products, food and neutraceuticals with Narula. India is a rice based country. It would be easier to sell rice based anything there than here.
Painful song - woman
https://www.youtube.com/watch?v=UNoouLa7uxA&ab_channel=Jewel
I resemble that remark
I know you were kidding becuase I know you are "crazy". And I love "crazy"
CC excerpts
Bradley
And as we continue to grow, we should see operating leverage, expand our gross margin, leading to sustainable profitability. We've built a viable, streamlined, efficient platform for profitable growth. During the past year, we've been introduced several new product lines. In 2022 we'll introduce even more.
Mitchel
As a result, we remain optimistic that what we believe is a discount to fair value will be reduced with continued improvement in our operations, and that we will be able to regain compliance organically. With that, I'll turn the call back to Peter for closing comments. Peter, can you hear us?
Mitchell
Hi Mark, it's Todd. I think, that Q1's trends follow on the latter half of the fourth quarter. I wouldn't go -- I don't want to use our December which was very strong for us as a benchmark going forward. But overall, I think, the trends remain positive and certainly, we're well ahead in terms of revenue and EBITDA vis -a - vis some of the quarters we saw in midyear last year.
Dr. William Peters
Okay, great. Hi, guys. Good numbers. Thank you for taking my call. I just want to make a request. Simple request. If Investor Relations or public relations, that our IBT employees can keep investors more informed with news such as new product update or new customers? And I think that will help retail investors stay more informed. And I think, that will help you fulfill your 180 day grace period with more retail investors coming and buying into RiceBran because they are more informed. That being said, usually we're waiting until earnings report that comes out and you've had a very good earnings report, it will be nice throughout the whole year that we had a little bit more information so we can feed off of that.
Bradley
It's one of our objectives for this year, is just to be more productive in our communication. We spent 2021, dealing with getting the operations to a level, but we recognize we need to improve our communications, particularly with postings on the website and press releases. The well to keep everybody informed, then, all stakeholders from investors, but also into customers. So appreciate your comment, your sentiment's well taken.
George Melas
Okay. Thank you. Good afternoon, Peter and Todd, and congratulations for the improvement, especially in the fourth quarter. Can you -- I think that the business reaching EBITDA breakeven is dependent upon further growth of the top line. Can you help us understand the revenue capacity of the various businesses of Dillon MGI, Golden Ridge, and then the core SRB business. Help us frame how big these could be based on your current relationships.
Bradley
And I think, George, you'll start to see that and may see some little movement in Q1, but I expect to see that more in Q2 and Q3. As we bring -- as we start to access new markets in there. In terms of -- I don't see overall capacity really being the growth limiter. Yes, we have a lot of demand for our derivatives that we manage, but I don't see it as a major limiting factor, particularly through 2022.
$RIBT Seeking Alpha earnings call transcript.
https://seekingalpha.com/article/4496332-ricebran-technologies-ribt-q4-2021-results-earnings-call-transcript
Dew, we all know BYND is floundering. Impossible is private, but saying they are doing well. I say BS to that. There is incredible new competition from smaller companies. The party is over, IMO.
I would like to thank the second caller asking for more PR's. OK call by me. Best is yet to come, upswing has started.
RiceBran Technologies Reports Fourth Quarter and Full Year 2021 Results
https://greenstocknews.com/news/nasdaq/ribt/ricebran-technologies-reports-fourth-quarter-and-full-year-2021-results
Impossible Foods founder to step down ....
....outgoing Chobani president to be CEO
https://www.fooddive.com/news/impossible-founder-steps-down-outgoing-chobani-president-to-be-ceo/620578/
Dive Brief:
Pat Brown, who founded Impossible Foods a decade ago and transformed the company into a plant-based meat giant, is stepping down as CEO, according to a blog post. Brown will continue his role as director and become Impossible Foods' chief visionary officer, responsible for research and technology innovation, strategic initiatives and public advocacy.
Peter McGuinness, who is leaving Chobani after serving as its president and COO, will become CEO and director of Impossible Foods on April 4. In choosing McGuinness, Brown cited his ability to push Chobani into new categories, and said he will help Impossible continue to expand and evolve its brand and business. The two will work together to lead Impossible and craft its long-term strategy.
Beyond McGuinness' corporate experience, Brown noted his commitment to Impossible's mission of addressing the threat of climate change caused by animal agriculture. The change in leadership comes after a busy 2021 for the plant-based meat pioneer, filled with product introductions, an international expansion and a $500 million fundraising round.
Dive Insight:
Pat Brown has provided the face, the scientific gravitas and the to-the-point snarky optimism for Impossible Foods since the company’s founding in 2011. But as the company reaches an inflection point and begins to reach a larger commercial audience, it needs a proven business leader in the food business to bring it through the next set of challenges.
In McGuinness, Impossible will now have a CEO who not only has deep experience in the food business, but who also has taken a niche brand and expanded it into many other areas of the grocery store. Chobani began in 2005 as a startup that brought Greek yogurt to the world. It is now a titan with net sales of more than $1.4 billion in FY 2020, according to a filing with the U.S. Securities and Exchange Commission. The company has expanded to a plethora of categories, including plant-based yogurts, coffee, peanut butter and milk.
"The industry needs a new playbook, and I feel like we have that playbook," McGuinness told Food Dive in a 2019 interview about Chobani. "We have a bit of an ax to grind. It's strange that there has been so much innovation in industries. There's been so much competition and breaking apart of industries that's fueling innovation and new frontiers, but [food has] been dominated by the big three food companies since World War II."
That’s one place where McGuinness is in complete agreement with Brown — and the entire ethos of Impossible Foods. Brown, a medical doctor who had a storied career developing new ways to look at genes and revolutionizing scientific publishing, founded Impossible Foods as a way to use his training and knowledge to improve the food system, both for the environment and for consumers. Brown is well known for his straight talk on the food system, and repeatedly has said that his company’s goal is to eradicate animal agriculture by 2035.
In the past two years, the reach and breadth of Impossible Foods’ products has grown exponentially. As the pandemic started shutting down restaurants’ dining rooms — where Impossible Foods made its name and did the bulk of its business — the company kicked into overdrive and made a huge retail expansion. In 2020 alone, Impossible Foods went from having products in 150 stores in January to more than 11,000 stores in December.
In 2021, Impossible added several new products. Impossible Sausage hit grocery store shelves in August. Impossible Chicken Nuggets — the company's first chicken analog product — became available in foodservice and at grocery stores in September, while Impossible Pork hit foodservice. Impossible Meatballs, which are made from a blend of the company's plant-based burgers and sausage, debuted in November.
The company has said it has many more products on the way. At a 2020 virtual media event, Impossible’s scientists showed off a prototype of Impossible Milk. The company has also mentioned it is working on areas including steak and seafood, and it set off on a 2020 drive to double its R&D team to bring more scientists of all disciplines aboard.
As chief visionary officer, Brown will be doing many of the things he is best known for at Impossible: leading innovation, strategic initiatives, public advocacy and the company’s mission.
It is not uncommon for a founding CEO to step back from the role as companies grow. In the cultured meat space, this has included the founders of both Future Meat Technologies and MeaTech 3D. Both companies were succeeded by experienced business professionals as their companies moved to a more commercial role.
Coming off of his success at Chobani, McGuinness is primed for this new role. His perspective and experience can help Impossible further diversify its offerings and find success. And McGuinness will have a lot to work with. Last year, which saw massive funding rounds for food companies, Impossible took the prize for the largest single investment round, bringing its lifetime funding to more than $2 billion.
Impossible Foods founder to step down ....
....outgoing Chobani president to be CEO
https://www.fooddive.com/news/impossible-founder-steps-down-outgoing-chobani-president-to-be-ceo/620578/
Dive Brief:
Pat Brown, who founded Impossible Foods a decade ago and transformed the company into a plant-based meat giant, is stepping down as CEO, according to a blog post. Brown will continue his role as director and become Impossible Foods' chief visionary officer, responsible for research and technology innovation, strategic initiatives and public advocacy.
Peter McGuinness, who is leaving Chobani after serving as its president and COO, will become CEO and director of Impossible Foods on April 4. In choosing McGuinness, Brown cited his ability to push Chobani into new categories, and said he will help Impossible continue to expand and evolve its brand and business. The two will work together to lead Impossible and craft its long-term strategy.
Beyond McGuinness' corporate experience, Brown noted his commitment to Impossible's mission of addressing the threat of climate change caused by animal agriculture. The change in leadership comes after a busy 2021 for the plant-based meat pioneer, filled with product introductions, an international expansion and a $500 million fundraising round.
Dive Insight:
Pat Brown has provided the face, the scientific gravitas and the to-the-point snarky optimism for Impossible Foods since the company’s founding in 2011. But as the company reaches an inflection point and begins to reach a larger commercial audience, it needs a proven business leader in the food business to bring it through the next set of challenges.
In McGuinness, Impossible will now have a CEO who not only has deep experience in the food business, but who also has taken a niche brand and expanded it into many other areas of the grocery store. Chobani began in 2005 as a startup that brought Greek yogurt to the world. It is now a titan with net sales of more than $1.4 billion in FY 2020, according to a filing with the U.S. Securities and Exchange Commission. The company has expanded to a plethora of categories, including plant-based yogurts, coffee, peanut butter and milk.
"The industry needs a new playbook, and I feel like we have that playbook," McGuinness told Food Dive in a 2019 interview about Chobani. "We have a bit of an ax to grind. It's strange that there has been so much innovation in industries. There's been so much competition and breaking apart of industries that's fueling innovation and new frontiers, but [food has] been dominated by the big three food companies since World War II."
That’s one place where McGuinness is in complete agreement with Brown — and the entire ethos of Impossible Foods. Brown, a medical doctor who had a storied career developing new ways to look at genes and revolutionizing scientific publishing, founded Impossible Foods as a way to use his training and knowledge to improve the food system, both for the environment and for consumers. Brown is well known for his straight talk on the food system, and repeatedly has said that his company’s goal is to eradicate animal agriculture by 2035.
In the past two years, the reach and breadth of Impossible Foods’ products has grown exponentially. As the pandemic started shutting down restaurants’ dining rooms — where Impossible Foods made its name and did the bulk of its business — the company kicked into overdrive and made a huge retail expansion. In 2020 alone, Impossible Foods went from having products in 150 stores in January to more than 11,000 stores in December.
In 2021, Impossible added several new products. Impossible Sausage hit grocery store shelves in August. Impossible Chicken Nuggets — the company's first chicken analog product — became available in foodservice and at grocery stores in September, while Impossible Pork hit foodservice. Impossible Meatballs, which are made from a blend of the company's plant-based burgers and sausage, debuted in November.
The company has said it has many more products on the way. At a 2020 virtual media event, Impossible’s scientists showed off a prototype of Impossible Milk. The company has also mentioned it is working on areas including steak and seafood, and it set off on a 2020 drive to double its R&D team to bring more scientists of all disciplines aboard.
As chief visionary officer, Brown will be doing many of the things he is best known for at Impossible: leading innovation, strategic initiatives, public advocacy and the company’s mission.
It is not uncommon for a founding CEO to step back from the role as companies grow. In the cultured meat space, this has included the founders of both Future Meat Technologies and MeaTech 3D. Both companies were succeeded by experienced business professionals as their companies moved to a more commercial role.
Coming off of his success at Chobani, McGuinness is primed for this new role. His perspective and experience can help Impossible further diversify its offerings and find success. And McGuinness will have a lot to work with. Last year, which saw massive funding rounds for food companies, Impossible took the prize for the largest single investment round, bringing its lifetime funding to more than $2 billion.
Yep copy, I thought that was either you or Besdin
Nice print for $RIBT Size: 146100 Price(at the ask): 0.3978 Amount: $58,118.58 Time: 1039
Sorry, I did not think of posting that story on your sites, my bad
I sure hope they have a good conference call tomorow. In the past the stock wouls have a pre earnings ralley, then fizzle with a so so CC. Maybe this time with a dip instead of a rally it goes up this time after hours tomorrow and Friday.
That figure is the days shorts, not the total. Shorts are not a problem, just a slight increase.
53% of RIBT's trades Monday were shorts, 50% yesterday. Not unusual They should start covering today with the CC tomorrow. It just went down and tested the 34 day MA at .36. I hope it holds.
https://fintel.io/ss/us/ribt
Market Date FINRA
Non-Exempt Volume FINRA
Exempt Volume FINRA
Short Volume FINRA
Total Volume FINRA
Short Volume Ratio
2022-03-15 602,807 + 26,829 = 629,636 / 1,256,598 = 50.11
2022-03-14 1,635,602 + 24,437 = 1,660,039 / 3,095,043 = 53.64
2022-03-11 866,478 + 22,797 = 889,275 / 1,701,411 = 52.27
2022-03-10 5,936,695 + 73,577 = 6,010,272 / 11,252,443 = 53.41
2022-03-09 138,997 + 11,607 = 150,604 / 279,940 = 53.80
2022-03-08 507,451 + 5,703 = 513,154 / 917,838 = 55.91
2022-03-07 731,011 + 27,938 = 758,949 / 1,290,148 = 58.83
2022-03-04 1,395,247 + 6,443 = 1,401,690 / 3,046,502 = 46.01
2022-03-03 1,627,520 + 3,056 = 1,630,576 / 2,958,854 = 55.11
2022-03-02 59,427 + 0 = 59,427 / 96,824 = 61.38
New CSU, Bill Gates funded rice bran study>>>>>
Non-Targeted Dried Blood Spot-Based Metabolomics Analysis
Showed Rice Bran Supplementation Effects Multiple Metabolic
Pathways during Infant Weaning and Growth in Mali
file:///C:/Users/George/Downloads/nutrients-14-00609-v2.pdf
Abstract: Rice bran contains essential nutrients, antioxidants, and bioactives with anti-inflammatory
and diarrheal protective properties important for infants. This 6-month randomized controlled trial investigated the effects of heat-stabilized rice bran supplementation during Malian infant weaning. Fifty
healthy 6-month-old infants were randomized to a rice bran intervention (N = 25) or non-intervention
control group (N = 25). Intervention infants received dose-escalating rice bran supplementation for
6 months (1–5 g/day). Monthly infant dried blood spot and anthropometric measurements were
collected. Dried blood spot metabolite abundances were compared monthly according to diet for
six months. Supplementation resulted in favorable weight-for-age and weight-for-length z-score
changes. Non-targeted dried blood spot-based metabolomics identified 796 metabolites, of which 33%
had significant fold differences between groups (7–12 months). Lipids and amino acids represented
70.6% of the metabolites identified. Rice bran supplementation during infant weaning significantly
modulated the metabolites involved in antioxidant defenses and with neuroactive properties including reduced glutathione, glycine, glutamate, cysteinylglycine, tryptophan betaine, and choline.
These findings support rice bran as a weaning ingredient to meet infant nutritional requirements and
with the potential to reduce oxidative stress and improve cognitive outcomes. This study provides
evidence for dried blood spots as a cost-effective tool to detect infant biomarkers of nutritional and
metabolic status.
5. Conclusions
Our data analysis of DBS-based non-targeted metabolomics points to the potential for
heat-stabilized rice bran supplementation to positively improve weaning infant nutritional
outcomes important in the first 1000 days of life. Rice bran impacted multiple metabolic
pathways, including infant antioxidant defenses, lipid profiles, and neuroactive molecules.
DBS-based metabolomics were sensitive to support rice bran as a food ingredient providing
important nutrients during weaning, which is especially influential in LMIC settings where
multi-nutrient deficiency and food insecurity are common. Supplementation also positively
impacted child growth measures, as seen in the favorable changes in WAZ and WLZ among
rice bran-fed infants.
Rice bran is an underutilized crop co-product from processing/milling that could
provide integrated agricultural/nutritional diversification while reducing food waste. Furthermore, heat-stabilized rice bran product development for human consumption requires
limited additional energy or land use, thus contributing to environmental sustainability.
The interplay of rice bran occurs with roles in environmental, economic, and nutritional
contexts, and this powerful, nutrient-dense food may improve global food security through
valorization. Coordinated regional and multi-national agricultural and health strategies are
necessary for sustainable production and adoption of rice bran based on the local context.
Forget about the Masters, it will be mine
Congrats mick and thanks for all the support you give everybody, you are one of a kind!!!!
Just showing Gates interest in rice. I saw a Gates funded CSU study out this year, it is ongoing studies.
file:///C:/Users/George/Downloads/nutrients-14-00609-v2.pdf
Gates has been into rice BRAN as well since 2010. Elizabeth Ryan has used RIBT's rice in studies.
https://csuventures.org/csu-rice-bran-researcher-receives-phase-ii-gates-foundation-funding/
CSU Rice Bran Researcher Receives Phase II Gates Foundation Funding
FORT COLLINS – Colorado State University announced today that it will receive Phase II funding through Grand Challenges Explorations, an initiative created by the Bill & Melinda Gates Foundation that enables individuals worldwide to test bold ideas to address persistent health and development challenges.
Elizabeth Ryan, an assistant professor in the College of Veterinary Medicine and Biomedical Sciences, will continue to pursue an innovative global health research project, titled “Studying How Rice Bran Augments Mucosal Immunity.”
Ryan will use the $1 million grant to study rice bran’s ability to fight off multiple gut pathogens such as Salmonella and Rotovirus that contribute to significant morbidity and mortality of many children around the world. Rice bran – the discarded brown covering on white rice grains – has untapped health properties that could help millions of people, Ryan said.
“The number of kids who are dying of diarrhea around the world every day deserves rigorous research attention with practical, wide-reaching solutions – there are so many pathogens, and over time it wears on your gut, immunity and ability to grow,” Ryan said. “It’s very hard to vaccinate against all these bugs at the exposure levels that exist.”
Colorado State University recently was recognized by Best Colleges Online as one of the 15 top universities in the nation fighting world hunger.
In 2010, Ryan was awarded a Phase I grant for her program. Grand Challenges Explorations (GCE) Phase I recognizes individuals worldwide who are taking innovative approaches to some of the world’s toughest and persistent global health and development challenges. GCE invests in the early stages of bold ideas that have real potential to solve the problems people in the developing world face every day. Phase II recognizes those ideas that have made significant progress toward implementation.
Ryan’s project is one of the Phase II Grand Challenges Explorations grants announced earlier this month.
“Investments in innovative global health research are already paying off,” said Chris Wilson, director of Global Health Discovery and Translational Sciences at the Bill & Melinda Gates Foundation. “We’re excited that we consistently receive so many surprising ideas from around the world and that we’re able to provide a second round of funding for some of the most unconventional among them.”
Ryan, who is based in Environmental and Radiological Health Sciences, will also identify and test bran from rice varieties around the globe with her co-principal investigators: Professor Steve Dow, who is Clinical Sciences and a leader in mucosal immunology, and University Distinguished Professor Jan Leach in the College of Agricultural Sciences.
Earlier this year, these researchers published a paper in the scientific, peer-reviewed journal BMC Microbiology showing that whole rice bran supplementation to the diet reduced susceptibility of mice to infection with a specific strain of Salmonella and potentially via induction of healthy gut bacteria known as Lactobacillus.
“We’ve shown that rice bran can inhibit colonization of Salmonella in the gut as well as induce mucosal immunity,” Ryan said. “Rice bran has chemical and pre-biotic properties that could have tremendous global health impact by basically preventing and reducing the severity of diarrheal infections.”
Whole grain brown rice from select varieties have long been used for anti-inflammatory properties in Ryan’s native India as part of a medicinal system known as Ayurveda. Furthermore, the bran could protect the human gut from disease much like it protects the rice grain from pests and microbes in the fields, Ryan said. The one caveat is that the bran must be heat stabilized immediately after it’s polished off the grain – this would extend its shelf life for human consumption and even its current use as feed for pigs and cattle.
Rice varieties have been improved largely for agricultural growing purposes, but not for health purposes. But she’s working with Leach, one of the world’s authorities on rice and how plants defend themselves against pathogens, to ensure studies focus on varieties that farmers are planting.
About Grand Challenges Explorations
Grand Challenges Explorations is a $100 million initiative funded by the Bill & Melinda Gates Foundation. Launched in 2008, more than 700 people in 45 countries have received Grand Challenges Explorations grants. The grant program is open to anyone from any discipline and from any organization. The initiative uses an agile, accelerated grant-making process with short two-page online applications and no preliminary data required. Initial grants of $100,000 are awarded two times a year. Successful projects have the opportunity to receive a follow-on grant of up to $1 million.
RIBT 92,275 shares trades after hours, up to $.4730 ,up 6.29% after hours above the official close. Yes pre market and after hours can suck, but nice volume here.
https://ih.advfn.com/stock-market/NASDAQ/ricebran-technologies-RIBT/trades?_ga=2.256236424.2012683222.1554897425-334505475.1554897425
RIBT 92,275 shares trades after hours, up to $.4730 ,up 6.29% after hours above the official close. Yes pre market and after hours can suck, but nice volume here.
https://ih.advfn.com/stock-market/NASDAQ/ricebran-technologies-RIBT/trades?_ga=2.256236424.2012683222.1554897425-334505475.1554897425
Welcome Glen0. I see some good posts of your at other boards and 568 followers. You will post good info, I am sure. Orions is my favorite "listed" stock boards.
https://investorshub.advfn.com/boards/profile.aspx?user=1756